Takeda Announces Massive Layoffs, Cutting Over 600 US Jobs

Restructuring plan aims to save $1.25 billion by 2028 to fund new drug launches.

Mar. 30, 2026 at 2:55pm

Got story updates? Submit your updates here. ›

Takeda Pharmaceutical has announced a major restructuring that will result in the loss of over 600 jobs across its U.S. operations. The layoffs, which include 247 employees in Cambridge, Massachusetts, are part of the company's efforts to streamline corporate functions and offset investments in new drug development and strategic technology initiatives.

Why it matters

Takeda's layoffs are the latest in a series of workforce reductions that have impacted the pharmaceutical industry in recent years. The cuts reflect the intense competition and financial pressures facing drug companies as they navigate patent cliffs, regulatory hurdles, and the need to invest in promising new therapies.

The details

According to a WARN Act notice, Takeda plans to lay off around 634 U.S. employees as part of its business transformation. The cuts will take place between July 1, 2026 and December 31, 2027, and will include 247 employees in Cambridge, Massachusetts. Takeda says the restructuring is expected to save over $1.25 billion by fiscal year 2028, which will help fund investments in new drug launches, late-stage pipeline progress, and strategic technology initiatives.

  • Takeda began notifying employees of the layoffs on March 25, 2026.
  • The 247 job cuts in Cambridge, Massachusetts will take effect between July 1, 2026 and December 31, 2027.

The players

Takeda Pharmaceutical

A Japan-based global pharmaceutical company that develops and markets medicines for oncology, gastroenterology, neuroscience, rare diseases, plasma-derived therapies, and vaccines.

Got photos? Submit your photos here. ›

What’s next

Takeda expects to submit a new drug application for its oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib in fiscal year 2026, which could help offset the impact of the layoffs.

The takeaway

Takeda's latest round of job cuts reflects the ongoing challenges facing the pharmaceutical industry, as companies balance the need to invest in new drug development with the pressure to control costs and streamline operations. The layoffs underscore the intense competition and financial pressures that drug makers must navigate in order to remain competitive.